SWOT Analysis for Tempest Therapeutics Inc

Rising Net Cash Flow and Cash from Operating activity
Relative Outperformance versus Industry over the Quarter (3 Months)
Annual Profit Growth higher than Sector Profit Growth
PEG lower than Industry PEG
Relative Outperformance versus Industry over 1 Week
Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years
Annual Net Profits improving for last 2 years
Stock with Low PE (PE < = 10)
Stocks Outperforming their Industry Price Change in the Quarter

Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score
Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Inefficient use of assets to generate profits - ROA declining in the last 2 years
Highest fall from 52 Week High
Top Losers
Low Piotroski Score : Companies with weak financials
Book Value Per Share deteriorating for last 2 years
Weak Momentum: Price below Short, Medium and Long Term Averages
Declining profits every quarter for the past 4 quarters
Top Losers

Mutual Funds Increased Shareholding in Past Month
Institutions increasing their shareholding
Mutual Funds Increased Shareholding over the Past Two Months
MFs increased their shareholding last quarter
Mf buying for 2 months

Tempest Therapeutics Inc SWOT Analysis: Strengths, Weakness, Opportunity, and Threats